WuXi PharmaTech: Q1 Revenues up 23%; Earnings Flat

WuXi PharmaTech, China's largest CRO/CMO, reported 2015 Q1 earnings grew 23% from the year earlier to $180 million, but GAAP net income was flat at $17.8 million. Dr. Ge Li, WuXi's Founder, President and CEO, blamed higher labor costs in China and investments in business expansion for lower margins. In the conference call, Dr. Li added that WuXi is talking with partners about several co-development projects and also contemplating a number of acquisitions. More details.... Stock Symbol: (NYSE: WX) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.